Radius Health, Inc. Form 4 November 22, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB APPROVAL

OMB 3235-0287 Number:

January 31, Expires: 2005

0.5

burden hours per response...

Estimated average

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * **GADICKE ANSBERT**

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

Radius Health, Inc. [NONE]

(Check all applicable)

(First) (Last)

(Middle)

3. Date of Earliest Transaction

(Month/Day/Year)

11/18/2011

X_ Director Officer (give title

10% Owner Other (specify

C/O MPM ASSET MANAGEMENT, 200

CLARENDON ST., 54TH FLOOR

(Street)

(State)

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

below)

BOSTON, MA 02116

(City)

(Instr. 3)

1. Title of 2. Transaction Date 2A. Deemed Security

(Month/Day/Year) Execution Date, if

(Month/Day/Year)

(Zip)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 3, 4 and 5) (Instr. 8)

5. Amount of 6. Ownership Securities Form: Direct Beneficially Owned (I) Following (Instr. 4)

7. Nature of Indirect (D) or Indirect Beneficial Ownership (Instr. 4)

Reported (A) Transaction(s) or (Instr. 3 and 4)

Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative

Conversion

3. Transaction Date 3A. Deemed

(Month/Day/Year) Execution Date, if

5. Number of TransactionDerivative

6. Date Exercisable and **Expiration Date**

7. Title and Amount of **Underlying Securities**

Edgar Filing: Radius Health, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A-1 Convertible Preferred Stock	Ш	11/18/2011		A	3,437	11/18/2011	<u>(1)</u>	Common Stock	34,370
Series A-1 Convertible Preferred Stock	<u>(1)</u>	11/18/2011		A	51,119	11/18/2011	<u>(1)</u>	Common Stock	511,190
Series A-1 Convertible Preferred Stock	<u>(1)</u>	11/18/2011		A	4,320	11/18/2011	<u>(1)</u>	Common Stock	43,200
Series A-1 Convertible Preferred Stock	<u>(1)</u>	11/18/2011		A	1,543	11/18/2011	<u>(1)</u>	Common Stock	15,430
Series A-1 Convertible Preferred Stock	Œ	11/18/2011		A	989	11/18/2011	<u>(1)</u>	Common Stock	9,890
Series A-1 Convertible Preferred Stock	(1)	11/18/2011		A	30,268	11/18/2011	<u>(1)</u>	Common Stock	302,680

Reporting Owners

Reporting Owner Name / Address		Relationships					
			10% Owner	Officer	Other		
GADICKE ANSBERT C/O MPM ASSET MANAGEMEN 200 CLARENDON ST., 54TH FL BOSTON, MA 02116		X	X				
Signatures							
/s/ Ansbert Gadicke	2/2011						

Reporting Owners 2

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each share of the Series A-1 Convertible Preferred Stock has no expiration date and is convertible at any time, in whole or in part, at the election of the holder at a conversion rate of 10 shares of Common Stock for every 1 share of Series A-1 Convertible Preferred Stock.
- The reported securities are owned directly by MPM BioVentures III, L.P. ("BV III"). MPM BioVentures III GP, L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III. The reporting person is a member of MPM III LLC. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are owned directly by MPM BioVentures III-QP, L.P. ("BV III QP"). MPM III GP and MPM III LLC are the direct and indirect general partners of BV III QP. The reporting person is a member of MPM III LLC. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are owned directly by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG"). MPM III GP and MPM (4) III LLC are the direct and indirect general partners of BV KG. The reporting person is a member of MPM III LLC. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are owned directly by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel"). MPM III GP and MPM III LLC (5) are the direct and indirect general partners of BV Parallel. The reporting person is a member of MPM III LLC. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are owned directly by MPM Asset Management Investors 2003 BVIII LLC ("AM 2003"). The reporting person is a member of AM 2003. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are owned directly by MPM Bio IV NVS Strategic Fund, L.P. ("MPM NVS"). MPM BioVentures IV GP LLC and MPM BioVentures IV LLC ("BV IV LLC") are the direct and indirect general partners of MPM NVS. The reporting person is a member of BV IV LLC. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3